|From: NetworkNewsWire (Rep: 0)||Date: 03/31/2020 17:06|
|Forum: Penny Stocks - Msg #4568 - List POAI msgs ||Thread #674138814 (Rec: 0) |
|NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Helomics’ Continued Progress Toward Developing AI-Driven Predictive Model of Ovarian Cancer|
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020). Per the update, CancerQuest2020 (CCQ2020) is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome. Predictive models embody the knowledge from these profiles, creating a “computational expert” or a “virtual patient” that can be queried. “Despite some headwinds imposed by the current COVID-19 pandemic, the Helomics team has been working diligently to meet both our clinical testing priorities for ovarian cancer patients and their oncologists, as well as maintaining progress on data generation for CCQ2020,” Helomics President Gerald Vardzel said in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.